INOVIQ LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.525 AUD | -1.87% |
|
-17.97% | -21.05% |
| Apr. 19 | INOVIQ Concludes Analytical Validation for Ovarian Cancer Blood Test | MT |
| Apr. 15 | Fears of Middle East Conflict Escalation Quell Appetite for Australian Shares | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
INOVIQ Ltd is an Australia-based company. The Company is engaged in developing and commercializing exosome solutions and precision diagnostics to improve the diagnosis and treatment of cancer and other diseases. It operates in one segment, the research and development of cancer diagnostics. The Company has two products in market, which include hTERT ICC test and the EXO-NET Pan-Exosome. Its cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate and other cancers. The hTERT test is an immunocytochemistry (ICC) assay registered for the detection of human telomerase reverse transcriptase (hTERT) in cytopathology samples. It is used as an adjunct to urine cytology to help resolve indeterminate cytology results and identify patients with increased risk of bladder cancer. EXO-NET is a research use only (RUO) pan-exosome capture tool for the isolation of exosomes from body fluids including plasma, urine and saliva.
Calendar
2024-08-26
- Q4 2024 Earnings Release (Projected)
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -21.05% | 32.02M | |
| +2.00% | 42.59B | |
| +8.46% | 40.65B | |
| +49.22% | 40.57B | |
| -12.36% | 26.77B | |
| +8.96% | 24.81B | |
| -24.05% | 18.17B | |
| +29.27% | 12.05B | |
| -2.77% | 11.7B | |
| +7.04% | 11.1B |
- Stock Market
- Equities
- IIQ Stock
- News INOVIQ Ltd
- Inoviq Jumps More than 7% Following Receipt of Chinese Patent for Lung Cancer Detection
